PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.28%
Net income growth under 50% of TRVN's 35.19%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
720.76%
D&A growth of 720.76% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Some yoy growth while TRVN is negative at -177.36%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-18.24%
Both cut yoy SBC, with TRVN at -11.08%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-114.66%
Both reduce yoy usage, with TRVN at -389.51%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.66%
Both negative yoy AP, with TRVN at -108.35%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
139.41%
Some yoy usage while TRVN is negative at -141.75%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-139.67%
Both negative yoy, with TRVN at -23.13%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-28.06%
Both yoy CFO lines are negative, with TRVN at -34.79%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-383.87%
Both yoy lines negative, with TRVN at -100.00%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-383.87%
Both yoy lines negative, with TRVN at -163.36%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-88.00%
Negative yoy issuance while TRVN is 127.91%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.